Aligos Therapeutics, Inc. (ALGS) stock

ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value

$2.10+0.12 (+6.06%)

Close on Nov 13, 2026Market cap $26.23MP/E –Yield –

Aligos Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Aligos Therapeutics's price to book ratio was 0.4× on Nov 11, 2026, against 0.8× a year earlier. Over the last 5 years it ranged from 0.3× to 3.6×, with a median of 0.6×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.4×	−0.4
2025	Dec 31, 2025	0.8×	−1.8
2024	Dec 31, 2024	2.6×	+2.1
2023	Dec 29, 2023	0.5×	+0.2
2022	Dec 30, 2022	0.3×	−2.0
2021	Dec 31, 2021	2.3×	–

Where these numbers come from

Parsed from the XBRL in Aligos Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Aug 19, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALGS.

Compare: ALGS vs TSHA · ALGS vs ELOX · ALGS vs PRME · ALGS vs MOLN · ALGS vs OCGN

Company	Revenue	Growth
ALGS	$5.83M	+122.2%
TSHA	$5.49M	-13.1%
ELOX	–	–
PRME	–	–
MOLN	–	–
OCGN	–	–

Company

Next earnings (est.): Mar 4, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 82
Held by institutions: 18.4%
Auditor: Ernst & Young LLP
SEC CIK: 1799448

Advertisement
300 × 250

See a number that looks wrong?

Aligos Therapeutics price to book ratio

Price to Book Ratio at the end of each year

More Aligos Therapeutics figures